2010: Neuro-oncology is moving!

Roger Stupp*, Michael Weller

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The first randomized phase III trial in patients with primary central nervous system lymphoma was reported for the first time at the 2010 annual meeting of the American Society of Clinical Oncology, and concluded that the omission of whole brain radiotherapy from first-line treatment does not compromise survival. Two randomized trials investigated tailored treatment strategies for elderly patients with glioma and reached opposite conclusions. Novel treatment approaches in recurrent glioblastoma with alternating tumour treatment fields (NovoTTF), or antiangiogenic agents (cilengitide and bevacizumab) have been reported and updated. The role of vascular endothelial growth factor-inhibiting strategies in the management of recurrent glioma remains unclear and controversial.

Original languageEnglish (US)
Pages (from-to)553-555
Number of pages3
JournalCurrent Opinion in Neurology
Issue number6
StatePublished - Dec 1 2010

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of '2010: Neuro-oncology is moving!'. Together they form a unique fingerprint.

Cite this